Form 4: Roivant Sciences President Sells Shares
Insider Transaction (Form 4)
Mayukh Sukhatme, President & CIO and a Director of Roivant Sciences Ltd., sold 335,174 shares of common stock on August 19, 2026.
Summary
- Option exercise/conversion: acquired 172,899 Common Shares at $3.85 ($665,661) on August 19, 2026; holds 18,803,638 after (Direct).
- Open-market sale: disposed of 172,899 Common Shares at $37.17 ($6,426,656) on August 19, 2026; holds 18,630,739 after (Direct).
- Option exercise/conversion: acquired 17,519 Common Shares at $3.85 ($67,448) on August 20, 2026; holds 18,648,258 after (Direct).
- Open-market sale: disposed of 17,519 Common Shares at $37.30 ($653,459) on August 20, 2026; holds 18,630,739 after (Direct).
- Option exercise/conversion: acquired 144,756 Common Shares at $3.85 ($557,311) on August 21, 2026; holds 18,775,495 after (Direct).
- Open-market sale: disposed of 144,756 Common Shares at $36.48 ($5,280,699) on August 21, 2026; holds 18,630,739 after (Direct).
- Option exercise/conversion: disposed of 172,899 Stock Option (Right to Buy) on August 19, 2026; holds 13,386,638 after (Direct).
- Option exercise/conversion: disposed of 17,519 Stock Option (Right to Buy) on August 20, 2026; holds 13,369,119 after (Direct).
- Option exercise/conversion: disposed of 144,756 Stock Option (Right to Buy) on August 21, 2026; holds 13,224,363 after (Direct).
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $12,360,813 of stock on the open market.
Insider Transactions
Mayukh Sukhatme — Director, Officer (President & CIO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-19 | Option exercise/conversion | Common Shares | 172,899 | $4 | $665.7K | 18,803,638 |
| 2026-08-19 | Open-market sale | Common Shares | 172,899 | $37 | $6.4M | 18,630,739 |
| 2026-08-20 | Option exercise/conversion | Common Shares | 17,519 | $4 | $67.4K | 18,648,258 |
| 2026-08-20 | Open-market sale | Common Shares | 17,519 | $37 | $653.5K | 18,630,739 |
| 2026-08-21 | Option exercise/conversion | Common Shares | 144,756 | $4 | $557.3K | 18,775,495 |
| 2026-08-21 | Open-market sale | Common Shares | 144,756 | $36 | $5.3M | 18,630,739 |
| 2026-08-19 | Option exercise/conversion | Stock Option (Right to Buy) | 172,899 | — | — | 13,386,638 |
| 2026-08-20 | Option exercise/conversion | Stock Option (Right to Buy) | 17,519 | — | — | 13,369,119 |
| 2026-08-21 | Option exercise/conversion | Stock Option (Right to Buy) | 144,756 | — | — | 13,224,363 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-19 | Option exercise/conversion (172,899 shares) |
| 2026-08-19 | Open-market sale (172,899 shares) |
| 2026-08-20 | Option exercise/conversion (17,519 shares) |
| 2026-08-20 | Open-market sale (17,519 shares) |
| 2026-08-21 | Option exercise/conversion (144,756 shares) |
| 2026-08-21 | Open-market sale (144,756 shares) |
| 2026-08-19 | Option exercise/conversion (172,899 shares) |
| 2026-08-20 | Option exercise/conversion (17,519 shares) |
| 2026-08-21 | Option exercise/conversion (144,756 shares) |
Keywords
insider transaction, Form 4, ROIV, Roivant Sciences Ltd., bearish, Mayukh Sukhatme
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.